. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Leukemia. 2021 Mar 2;35(9):2539–2551. doi: 10.1038/s41375-021-01179-4

Table 4.

Pretreatment characteristics for the 205 maintenance patients by treatment arm

	Midostaurin (N=120)	Placebo (N=85)	p-value^*
Age, median years (range)	48 (20–60)	51 (19–60)	0.06¹
Female, N (%)	56 (47%)	47 (55%)	0.22²
FLT3 mutation, N (%)			0.67²
TKD (No ITD)	32 (27%)	27 (32%)
ITD (ratio <0.7)	61 (51%)	42 (49%)
ITD (ratio ≥0.7)	27 (23%)	16 (19%)
ELN 2017, N (%)			0.24²
Favorable	43 (54%)	37 (63%)
Intermediate	19 (24%)	14 (24%)
Adverse	17 (22%)	8 (14%)
Pre-treatment WBC, x10³/ul, median (range)	30.4 (0.6–421.8)	38.3 (1.2–231.0)	0.70¹

p-values

^1:

Kruskal Wallis

^2:

Chi Square